Simon Adrian Georg, Lyu Su Ir, Schultheis Anne Maria, Stahl David, Wuerdemann Nora, Walter Sebastian, Hieggelke Lena, Buettner Reinhard, Bruns Christiane Josephine, Eysel Peer, Schiffmann Lars Mortimer, Knipper Karl, Mallmann Peter, Quaas Alexander, Ullrich Roland
Institute of Pathology, University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.
Institute for Surgical Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
Int J Cancer. 2025 Jun 1;156(11):2237-2250. doi: 10.1002/ijc.35310. Epub 2024 Dec 20.
This study evaluates the H2AX/γ-H2AX expression in soft tissue sarcomas (STS), its implications for biological behavior and immune environment, and its potential as a prognostic biomarker. RNA-Seq data from 237 STS were obtained from The Cancer Genome Atlas project. Patients were stratified by H2AX mRNA expression using a survival-associated cutoff. Differentially expressed genes and pathways as well as immune signatures between H2AX- and H2AX tumors were identified with DESeq2 analysis, gene set enrichment analyses (GSEA), Enrichr pathway analysis and CIBERSORTx. Tissue microarrays of a different cohort of 291 STS were generated for immunohistochemical staining to assess γ-H2AX protein expression, followed by statistical evaluation. High H2AX mRNA expression was associated with shorter overall survival (OS) in STS (p = 0.02), particularly in leiomyosarcomas (LMS) (p < 0.001), and was a negative prognostic factor in LMS (HR 11.15, p < 0.001). H2AX LMS tumors showed upregulation of cell cycle-related pathways, while H2AX LMS exhibited increased inflammatory activity, including elevated M1 macrophage signatures and resting mast cell signatures (both p < 0.001). High γ-H2AX protein levels were an independent negative prognostic factor in the total LMS cohort (HR 12.12, p = 0.025) and in the subgroup of non-uterine LMS (HR 153.80, p = 0.013). Consistent with CIBERSORTx analysis, γ-H2AX LMS showed higher mast cell infiltration than γ-H2AX LMS (p = 0.038). In conclusion, H2AX mRNA and γ-H2AX protein expression are associated with distinct biological behavior, differences in the immune cell environment, and might serve as useful prognostic biomarkers in LMS.
本研究评估了软组织肉瘤(STS)中H2AX/γ-H2AX的表达情况、其对生物学行为和免疫环境的影响以及作为预后生物标志物的潜力。来自癌症基因组图谱项目的237例STS的RNA测序数据。根据与生存相关的临界值,将患者按H2AX mRNA表达进行分层。通过DESeq2分析、基因集富集分析(GSEA)、Enrichr通路分析和CIBERSORTx确定H2AX高表达组和低表达组之间的差异表达基因、通路以及免疫特征。对另一组291例STS制作组织微阵列进行免疫组化染色,以评估γ-H2AX蛋白表达,随后进行统计学评估。高H2AX mRNA表达与STS患者的总生存期(OS)较短相关(p = 0.02),尤其是在平滑肌肉瘤(LMS)中(p < 0.001),并且是LMS的不良预后因素(HR 11.15,p < 0.001)。H2AX高表达的LMS肿瘤显示细胞周期相关通路上调,而H2AX低表达的LMS表现出炎症活性增加,包括M1巨噬细胞特征和静止肥大细胞特征升高(均p < 0.001)。高γ-H2AX蛋白水平是整个LMS队列(HR 12.12,p = 0.025)和非子宫LMS亚组(HR 153.80,p = 0.013)的独立不良预后因素。与CIBERSORTx分析一致,γ-H2AX高表达的LMS比γ-H2AX低表达的LMS显示出更高的肥大细胞浸润(p = 0.038)。总之,H2AX mRNA和γ-H2AX蛋白表达与不同的生物学行为、免疫细胞环境差异相关,并且可能作为LMS中有用的预后生物标志物。